Aptose Biosciences Inc APTO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if APTO is a good fit for your portfolio.
News
-
Aptose Announces Receipt of Deficiency Notice from Nasdaq
-
Aptose Announces Results from Annual and Special Meeting of Shareholders
-
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
-
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Aptose Reports Results for the First Quarter 2024
Trading Information
- Previous Close Price
- $0.57
- Day Range
- $0.55–0.60
- 52-Week Range
- $0.55–5.10
- Bid/Ask
- $0.55 / $0.57
- Market Cap
- $10.29 Mil
- Volume/Avg
- 95,391 / 68,230
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 36
- Website
- https://www.aptose.com
Valuation
Metric
|
APTO
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 65.17 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
APTO
|
---|---|
Quick Ratio | 0.77 |
Current Ratio | 0.97 |
Interest Coverage | — |
Quick Ratio
APTO
Profitability
Metric
|
APTO
|
---|---|
Return on Assets (Normalized) | −197.99% |
Return on Equity (Normalized) | −497.57% |
Return on Invested Capital (Normalized) | −451.85% |
Return on Assets
APTO
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Qsfxfjzk | Ydvj | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Pyfxnnd | Cxkfw | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Bfvdsgfw | Gbplpjx | $118.7 Bil | |||
Moderna Inc
MRNA
| Vppcdbwq | Fcjm | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Hgdfknnk | Lkhyq | $29.7 Bil | |||
argenx SE ADR
ARGX
| Brdfxwdk | Nrr | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Jqjwcdhl | Jygc | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Ggxmdhrr | Hwvssx | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Gcjrvphcv | Wlc | $15.0 Bil | |||
Incyte Corp
INCY
| Frmcjhf | Xdqgv | $13.5 Bil |